CRYO-CELL INTL DL-01
Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manu… Read more
CRYO-CELL INTL DL-01 (ZCY) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CRYO-CELL INTL DL-01 (ZCY) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CRYO-CELL INTL DL-01 - Net Assets Trend (None–None)
This chart illustrates how CRYO-CELL INTL DL-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CRYO-CELL INTL DL-01 (None–None)
The table below shows the annual net assets of CRYO-CELL INTL DL-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CRYO-CELL INTL DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CRYO-CELL INTL DL-01 Competitors by Market Cap
The table below lists competitors of CRYO-CELL INTL DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FarGlory Hotel Co Ltd
TW:2712
|
$10.71 Million |
|
Pact Group Holdings Ltd
PINK:PTTCF
|
$10.72 Million |
|
QT Imaging Holdings Inc. Common Stock
NASDAQ:QTI
|
$10.72 Million |
|
INFORMICA REAL INV
F:IDE
|
$10.73 Million |
|
Appasia Bhd
KLSE:0119
|
$10.71 Million |
|
Wall to Wall Group A
ST:WTW-A
|
$10.70 Million |
|
Hanchang Ind.Co.Ltd
KQ:079170
|
$10.70 Million |
|
Cybeats Technologies Corp.
PINK:CYBCF
|
$10.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CRYO-CELL INTL DL-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CRYO-CELL INTL DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CRYO-CELL INTL DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CRYO-CELL INTL DL-01's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $1,542,527,848
- Average return on equity (ROE) among peers: 7.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CRYO-CELL INTL DL-01 (ZCY) | €- | N/A | N/A | $10.71 Million |
| Raffles Medical Group Ltd (02M1) | $1.04 Billion | 8.64% | 0.46x | $548.22 Million |
| China Resources Medical Holdings Company Limited (1PH) | $6.14 Billion | 6.37% | 0.28x | $264.86 Million |
| Apollo Medical Holdings Inc (3AM) | $510.64 Million | 13.50% | 0.70x | $820.67 Million |
| NUVERRA ENVIR SOL (3H5) | $548.43 Million | -8.67% | 2.25x | $95.85 Million |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.04 Billion | 6.61% | 0.54x | $9.60 Million |
| Medicover AB (5M0B) | $562.10 Million | 18.11% | 2.00x | $967.15 Million |
| Ambea AB (publ) (6MA) | $4.68 Billion | 7.82% | 2.82x | $937.47 Million |
| Eifelhöhen-Klinik AG (EIF) | $18.66 Million | 24.17% | 2.10x | $4.38 Million |
| Garofalo Health Care S.p.A (GHC) | $333.14 Million | 6.51% | 1.55x | $126.70 Million |
| GZ4 (GZ4) | $545.91 Million | -4.85% | 4.17x | $116.32 Million |